|Videos|October 15, 2019

Implementing the "Train the Trainer" Program in South Africa

Debra Goff, PharmD, shares how the "Train-the-Trainer" program was implemented in South Africa with Pablo J. Sánchez, MD, and Pavel Prusakov, PharmD.

Segment Description: Debra Goff, PharmD, an infectious disease pharmacist at The Ohio State University Wexner Medical Center, shares how the "Train-the-Trainer" program was implemented in South Africa.

Interview transcript: (modified slightly for readability)

The NICU “Train-the-Trainer Antibiotic Stewardship Mentoring Program” for pharmacists got started in South Africa, in response to the CDC being called in by one of the largest hospitals in South Africa, where their neonatal unit was having an outbreak of carbapenem-resistant Enterobacteriaceae infections, resulting in the death of multiple babies.

So they called for help and the CDC knew of my program in adult medicine mentoring program for stewardship, and asked if I could help train their pharmacists to become intimately involved in the day-to-day patient care interventions, because their current role was really just dispensing medication.

And so they asked me to help and that's really how the program came to be. Except, I don't have expertise in neonatal stewardship. My area of expertise is adults. I know how to implement the model, but it led to a beautiful collaborative relationship with my two colleagues Dr. Sanchez and Dr. Prusakov who are world-renowned neonatal experts and run the very successful Nationwide Children's Hospital stewardship program. So I collaborated with them so we could go in as a team to provide this mentoring program for South Africa pharmacists.

Check out part 1 of this 3-part interview.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.